We read with great interest the recent results from the Spanish observational PORTO-DETECT cohort study.1 Briefly, the authors demonstrate that “early” portopulmonary hypertension (PoPH), defined by right heart catheterization according to the 2022 European Society of Cardiology and European Respiratory Society hemodynamic criteria (i.e. mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU)),2 identifies a subgroup of patients with markedly worse outcomes than those who have normal mPAP.
We read with great interest the recent results from the Spanish observational PORTO-DETECT cohort study.1 Briefly, the authors demonstrate that “early” portopulmonary hypertension (PoPH), defined by right heart catheterization according to the 2022 European Society of Cardiology and European Respiratory Society hemodynamic criteria (i.e. mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU)),2 identifies a subgroup of patients with markedly worse outcomes than those who have normal mPAP.